Association of Sp1 Tandem Repeat Polymorphism of ALOX5 with Coronary Artery Disease in Indian Subjects

Clinical and Translational Science

Volumn 5, Issue 5, 2012, Pages 408-411

  Todur, Seema P ^a   Ashavaid, Tester F ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

CAD; Genetics; India; Lipoxygenase; Polymorphisms

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BIOCHEMISTRY; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HETERODUPLEX ANALYSIS; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; TANDEM REPEAT;

ARACHIDONATE 5-LIPOXYGENASE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; MIDDLE AGED; NUCLEIC ACID HETERODUPLEXES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SP1 TRANSCRIPTION FACTOR; TANDEM REPEAT SEQUENCES;

EID: 84867719969     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2011.00396.x     Document Type: Article

References (23)

1. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990; 323: 645-655.
2. Radmark O. 5-lipoxygenase-derived leukotrienes: mediators also of atherosclerotic inflammation. Arterioscler Thromb Vasc Biol. 2003; 23: 1140-1142.
3. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004; 350: 29-37.
4. Allayee H, Baylin A, Hartiala J, Wijesuriya H, Mehrabian M, Lusis AJ, Campos H. Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction. Am J Clin Nutr. 2008; 88: 934-940.
5. Silverman ES, Du J, De Sanctis GT, Radmark O, Samuelsson B, Drazen JM, Collins T. Egr-1 and sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am J Respir Cell Mol Biol. 1998; 19: 316-323.
6. Enas EA. Coronary artery disease epidemic in indians: a cause for alarm and call for action. J Indian Med Assoc. 2000; 98: 694-695, 697-702.
7. Ashavaid TF, Todur SP, Dherai AJ. Health status of indian population-current scenario. J Assoc Physicians India. 2004; 52: 363-369.
8. Hirano T, Ito Y, Saegusa H, Yoshino G. A novel and simple method for quantification of small, dense ldl. J Lipid Res. 2003; 44: 2193-2201.
9. Ashavaid TF, Kondkar AA, Nair KG. Identification of two ldl-receptor mutations causing familial hypercholesterolemia in indian subjects by a simplified rapid pcr-heteroduplex method. Clin Chem. 2000; 46: 1183-1185.
10. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-874.
11. Radmark O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat. 2002; 68-69: 211-234.
12. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002; 91: 120-126.
13. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003; 100: 1238-1243.
14. Ashavaid TF, Shalia KK, Kondkar AA, Todur SP, Nair KG, Nair SR. Gene polymorphism and coronary risk factors in indian population. Clin Chem Lab Med. 2002; 40: 975-985.
15. Ashavaid TF, Todur SP, Nair KG. Apolipoprotein e polymorphism and coronary heart disease. J Assoc Physicians India. 2003; 51: 784-788.
16. Kondkar AA, Nair KG, Ashavaid TF. Genetic analysis of indian subjects with clinical features of possible type iia hypercholesterolemia. J Clin Lab Anal. 2007; 21: 375-381.
17. Herb F, Thye T, Niemann S, Browne EN, Chinbuah MA, Gyapong J, Osei I, Owusu-Dabo E, Werz O, Rusch-Gerdes S, et al. Alox5 variants associated with susceptibility to human pulmonary tuberculosis. Hum Mol Genet. 2008; 17: 1052-1060.
18. Wang J, John EM, Ingles SA. 5-lipoxygenase and 5-lipoxygenase-activating protein gene polymorphisms, dietary linoleic acid, and risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2748-2754.
19. Maznyczka A, Braund P, Mangino M, Samani NJ. Arachidonate 5-lipoxygenase (5-lo) promoter genotype and risk of myocardial infarction: a case-control study. Atherosclerosis. 2008; 199: 328-332.
20. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, Silverman ES, Collins T, Fischer AR, Keith TP, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 1997; 99: 1130-1137.
21. Silverman ES, Drazen JM. Genetic variations in the 5-lipoxygenase core promoter. Description and functional implications. Am J Respir Crit Care Med. 2000; 161: S77-S80.
22. Austin MA, Edwards KL, Monks SA, Koprowicz KM, Brunzell JD, Motulsky AG, Mahaney MC, Hixson JE. Genome-wide scan for quantitative trait loci influencing ldl size and plasma triglyceride in familial hypertriglyceridemia. J Lipid Res. 2003; 44: 2161-2168.
23. Rainwater DL, Almasy L, Blangero J, Cole SA, VandeBerg JL, MacCluer JW, Hixson JE. A genome search identifies major quantitative trait loci on human chromosomes 3 and 4 that influence cholesterol concentrations in small ldl particles. Arterioscler Thromb Vasc Biol. 1999; 19: 777-783.